华大基因：全资子公司拟与关联方联合申报科技项目

Core Viewpoint - The rapid identification of pathogens has become a critical component of public health prevention and clinical diagnosis, prompting the company to initiate a collaborative project aimed at developing a specialized pathogen detection system [1] Group 1: Project Overview - The company’s subsidiary, Tianjin BGI Medical Testing Co., Ltd., plans to jointly apply for a national science and technology major project focused on the development of a convenient long-read sequencing system for pathogen detection [1] - The total funding for the joint application project is 120 million yuan, with 20 million yuan requested from the national budget and 100 million yuan to be self-funded by the participating institutions [1] - Among the self-funded amount, Tianjin BGI Medical Testing Co., Ltd. will contribute 50 million yuan [1] Group 2: Project Participation - Tianjin BGI Medical Testing Co., Ltd. will participate in three specific topics within the project, focusing on the development of pathogen single-molecule detection kits, supporting algorithms, databases, and research on automation applications [1]